In non-small cell lung carcinoma, high levels of Bnip3 expression are associated with poor clinical outcome and in prostate cancer Bnip3 expression strongly correlates with the cancer stage or “Gleason” score [26, 28]. Here, BNIP3 is linked to prostate cancer.